25 related articles for article (PubMed ID: 21521796)
1. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
Draper AJ; Madan A; Parkinson A
Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
[TBL] [Abstract][Full Text] [Related]
2. Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites.
Los LE; Pitzenberger SM; Ramjit HG; Coddington AB; Colby HD
Drug Metab Dispos; 1994; 22(6):903-8. PubMed ID: 7895608
[TBL] [Abstract][Full Text] [Related]
3. Interspecies differences in stability kinetics and plasma esterases involved in hydrolytic activation of curcumin diethyl disuccinate, a prodrug of curcumin.
Ratnatilaka Na Bhuket P; Jithavech P; Ongpipattanakul B; Rojsitthisak P
RSC Adv; 2019 Jan; 9(8):4626-4634. PubMed ID: 35520191
[TBL] [Abstract][Full Text] [Related]
4. Proteomics and Metabolomics for Cystic Fibrosis Research.
Liessi N; Pedemonte N; Armirotti A; Braccia C
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751630
[TBL] [Abstract][Full Text] [Related]
5. Paraoxonase 1 (PON1) promoter (-107T/C) and coding region (192Q/R and 55L/M) genetic variations in pseudoexfoliation syndrome and pseudoexfoliative glaucoma risk.
Can Demirdöğen B; Koçan Akçin C; Göksoy E; Yakar G; Öztepe T; Demirkaya-Budak S; Oflaz S
Graefes Arch Clin Exp Ophthalmol; 2019 Oct; 257(10):2257-2270. PubMed ID: 31292763
[TBL] [Abstract][Full Text] [Related]
6. Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity.
Liu XW; Yang JL; Niu W; Jia WW; Olaleye OE; Wen Q; Duan XN; Huang YH; Wang FQ; Du FF; Zhong CC; Li YF; Xu F; Gao Q; Li L; Li C
Acta Pharmacol Sin; 2018 Dec; 39(12):1935-1946. PubMed ID: 30054600
[TBL] [Abstract][Full Text] [Related]
7. Maximum human objectively measured pharmacologically stimulated accommodative amplitude.
Grzybowski A; Schachar RA; Gaca-Wysocka M; Schachar IH; Pierscionek BK
Clin Ophthalmol; 2018; 12():201-205. PubMed ID: 29403261
[TBL] [Abstract][Full Text] [Related]
8. The Sweat Metabolome of Screen-Positive Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport.
Macedo AN; Mathiaparanam S; Brick L; Keenan K; Gonska T; Pedder L; Hill S; Britz-McKibbin P
ACS Cent Sci; 2017 Aug; 3(8):904-913. PubMed ID: 28852705
[TBL] [Abstract][Full Text] [Related]
9. Contributions of intestine and plasma to the presystemic bioconversion of vicagrel, an acetate of clopidogrel.
Qiu Z; Li N; Song L; Lu Y; Jing J; Parekha HS; Gao W; Tian F; Wang X; Ren S; Chen X
Pharm Res; 2014 Jan; 31(1):238-51. PubMed ID: 24037619
[TBL] [Abstract][Full Text] [Related]
10. Paraoxonase status and plasma butyrylcholinesterase activity in chlorpyrifos manufacturing workers.
Albers JW; Garabrant DH; Berent S; Richardson RJ
J Expo Sci Environ Epidemiol; 2010 Jan; 20(1):79-89. PubMed ID: 19223938
[TBL] [Abstract][Full Text] [Related]
11. Paraoxonases: ancient substrate hunters and their evolving role in ischemic heart disease.
Martinelli N; Consoli L; Girelli D; Grison E; Corrocher R; Olivieri O
Adv Clin Chem; 2013; 59():65-100. PubMed ID: 23461133
[TBL] [Abstract][Full Text] [Related]
12. Human paraoxonase 1 is the enzyme responsible for pilocarpine hydrolysis.
Hioki T; Fukami T; Nakajima M; Yokoi T
Drug Metab Dispos; 2011 Aug; 39(8):1345-52. PubMed ID: 21521796
[TBL] [Abstract][Full Text] [Related]
13. Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes.
Endo T; Ban M; Hirata K; Yamamoto A; Hara Y; Momose Y
Drug Metab Dispos; 2007 Mar; 35(3):476-83. PubMed ID: 17178767
[TBL] [Abstract][Full Text] [Related]
14. Paraoxonase activity against nerve gases measured by capillary electrophoresis and characterization of human serum paraoxonase (PON1) polymorphism in the coding region (Q192R).
Kanamori-Kataoka M; Seto Y
Anal Biochem; 2009 Feb; 385(1):94-100. PubMed ID: 18952040
[TBL] [Abstract][Full Text] [Related]
15. The common variant Q192R at the paraoxonase 1 (PON1) gene and its activity are responsible for a portion of the altered antioxidant status in type 2 diabetes.
Zargari M; Sharafeddin F; Mahrooz A; Alizadeh A; Masoumi P
Exp Biol Med (Maywood); 2016 Aug; 241(14):1489-96. PubMed ID: 27022137
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
